OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Tuesday, June 23rd GSAE, MGRM, NXHD, CGEN, WNBD, XDSL

Tue. June 23, 2009; Posted: 12:18 PM

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts.

GREEN STAR ALTERNATIVE ENERGY INCORPORATED (OTC: GSAE)

Detailed Quote: www.otcpicks.com/quotes/GSAE.php

Company Profile: http://www.otcpicks.com/Newsletter/GSAE_eProfile_091708.htm

Green Star Alternative Energy is an environmentally conscious, renewable energy producer. The Company is working to develop more than 300 MW (megawatts) of clean electricity through wind energy. The corporate revenue model is two-fold: the use of a renewable resource allows not only for the creation of environmentally friendly energy, but the granting of carbon (greenhouse gas) emission credits which may be traded and sold. Green Star is pursuing a significant opportunity to provide clean energy to the growing Republic of Serbia and neighbouring European countries. Through a joint venture with key wind farm and power trading company Notos, Green Star will become the nation's first developer of wind power. GSAE is focussed on green technology and sustainable energy programs like wind turbines, hydro electric power generation, and other renewable electricity models.

GSAE News:

June 22 - Wind Energy Specialist Joins Green Star/Notos Team

Green Star Alternative Energy, Inc. (OTC: GSAE | Quote | Chart | News | PowerRating) (Frankfurt: GAT) ("GSAE" or the "Company") announces the hiring of Nikola Vasilijevic as the Company's Wind Farm Designer. Nikola's expertise lies in electrical engineering and computer science; he will oversee the engineering and construction of Green Star's wind farms.

Nikola has worked for EPS, Electric Power Industry of Serbia, and has made significant research contributions to the assessment of wind energy potential in the region. His published work includes "Creating the Map of Vojvodina's Wind Potential Using Linear Interpolation Independent of Direction" (2008); and Nikola was an honorary presenter at the European Wind Energy Conference in Marseilles.

Miodrag Andric, CEO of Green Star Alternative Energy, stated: "The Company is assembling the team needed to begin the development phases of our corporate strategy, and Nikola's experience will prove most valuable during design and construction."

MONOGRAM BIOSCIENCES INCORPORATED (NASDAQ: MGRM | Quote | Chart | News | PowerRating) "Up 169.05% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/MGRM.php

Monogram Biosciences, Inc. is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. Monogram Biosciences, Inc.'s products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. Monogram Biosciences, Inc.'s technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics.

MGRM News:

June 23 - LabCorp Enters Definitive Agreement to Acquire Monogram Biosciences, Inc.

Laboratory Corporation of America Holdings (NYSE: LH) and Monogram Biosciences, Inc. (Nasdaq: MGRM | Quote | Chart | News | PowerRating) announced that they have entered into a definitive agreement and plan of merger under which LabCorp will acquire all of the outstanding shares of Monogram in a cash tender offer for $4.55 per share for an implied total equity value of approximately $106.7 million, or a total enterprise value of approximately $155 million at March 31, 2009, including net indebtedness.

"The transaction announced today is a significant step in the execution of LabCorp's strategy of leadership in personalized medicine," said David P. King, Chairman and Chief Executive Officer of LabCorp. "Monogram Biosciences, Inc. has an excellent clinical reputation, a market leading infectious disease test, a market leading companion diagnostic, an exciting technology platform for oncology and offers LabCorp a substantial growth opportunity. By utilizing LabCorp's national infrastructure to build on Monogram's already strong sales, we will advance our leadership in infectious disease and cancer testing, companion diagnostics and personalized medicine. We look forward to providing improved offerings to both our and Monogram's current customers."

Monogram Biosciences, Inc. is a leading provider of companion diagnostics - molecular diagnostic products that help guide and target appropriate treatments. Monogram's proprietary, clinically validated Trofile assay identifies patients who are eligible for the CCR5 class of HIV drugs and is the widely adopted companion diagnostic for the HIV drug Selzentry . Monogram's PhenoSense and PhenoSense GT HIV tests measure individual patient viral drug resistance, thereby enabling physicians to design optimal, individualized treatment plans for each patient. PhenoSense and PhenoSense GT are among the most widely used HIV resistance tests in the market today. Monogram's HIV tests are used routinely by physicians for managing patient therapy and are an integral component of anti-HIV drug development and clinical evaluations for the pharmaceutical industry.

Monogram's proprietary VeraTag technology has been used to develop a sensitive means to assess HER-2 status in tissue samples and has significant potential as a tool to help guide therapy decisions in breast cancer patients. Based on the VeraTag platform, Monogram has multiple tests in development for measuring a variety of protein markers that may have clinical utility to help guide treatment decisions across a broad range of cancer drugs. The potential oncology pipeline associated with this technology is a natural extension of LabCorp's existing oncology offerings for both clinical trials and commercial clients.

"The transaction underscores the fundamental value of the Monogram business, the talent and expertise of our global team and the quality of our offerings," said William D. Young, Chief Executive Officer and Chairman of Monogram Biosciences, Inc. "LabCorp has an exciting vision of the role of molecular diagnostics in personalized medicine, and we are excited to see Monogram's technology and employees become a part of that vision. We expect the transaction will significantly accelerate the development of products that will improve treatment outcomes for patients with infectious diseases and cancer."

The acquisition is expected to be approximately $0.12 dilutive to LabCorp's 2009 earnings per share (EPS), including approximately $0.04 of transaction related costs, and slightly accretive to 2010 EPS.

Under the terms of the agreement and plan of merger, LabCorp's acquisition subsidiary, Mastiff Acquisition Corp., will commence a tender offer to purchase all outstanding shares of Monogram Biosciences, Inc. for $4.55 per share in cash, without interest. Following the completion of the tender offer, LabCorp expects to merge Mastiff Acquisition Corp. and Monogram resulting in any shares not purchased in the tender offer being converted into the right to receive the same cash price per share as paid in the tender offer. The tender offer and the merger are subject to customary closing conditions set forth in the agreement and plan of merger, including the acquisition in the tender offer of a majority of Monogram's outstanding shares on a fully diluted basis (excluding out of the money options) and the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing of the acquisition is expected in the third quarter of 2009.

The Board of Directors of Monogram Biosciences, Inc. has unanimously determined that the offer and the merger are advisable, fair to, and in the best interests of Monogram and its stockholders, approved the agreement and plan of merger and the other transactions contemplated thereby, including the tender offer, and recommended that the Monogram stockholders accept the offer and tender their shares in the offer when it is made.

The total $155 million estimated enterprise value of the transaction is based on Monogram's approximately 23.5 million fully diluted shares outstanding less net cash and cash equivalents on hand as of March 31, 2009, plus outstanding indebtedness as of that date.

ABOUT LABCORP

Laboratory Corporation of America Holdings, a S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $4.5 billion in 2008, over 28,000 employees worldwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc., The Center for Esoteric Testing, Litholink Corporation, DIANON Systems, Inc., US LABS, and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp conducts clinical trial testing through its Esoterix Clinical Trials Services division. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies.

NEXIA HOLDINGS INCORPORATED (OTCBB: NXHD | Quote | Chart | News | PowerRating) "Up 100.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/NXHD.php

Nexia Holdings, Inc., headquartered in Salt Lake City, Utah, is a diversified holdings company with operations in real estate, health & beauty, and fashion retail. Nexia owns a majority interest in Landis Lifestyle Salon (www.landissalons.com), a hair salon built around the world-class Aveda product line. Through its Style Perfect, Inc. subsidiary, Nexia owns the innovative retail and design firm Black Chandelier and its related brands. Black Chandelier currently operates one retail location and online store at www.blackchandelier.com.

NXHD News:

June 22 - Nexia to Acquire $1M Worth of Preferred Stock in RBSY, Bringing Total Face Value of Portfolio Securities to $3.5M

Nexia Holdings, Inc. (OTC: NXHD | Quote | Chart | News | PowerRating) reported that it has executed a Stock Exchange Agreement with RoboServer Systems Corporation (RBSY) to exchange 200,000 shares of Nexia's restricted Series C Preferred Stock, with a stated conversion value of $1,000,000 for $1,000,000 of RoboServer's Preferred Stock. The closing on the exchange is to take place before June 27, 2009 pending the delivery of the necessary documentation to the respective transfer agents of the two parties to the agreement.

Mr. Surber, CEO of Nexia, commented, "With the acquisition of RBSY's convertible preferred shares, Nexia's portfolio of investment securities will have a face value of $3.5M. I am hopeful that Nexia will be able to convert portions of its investments into cash upon complying with Rule 144. Nexia just might be able to self finance the opening of multiple salons in the coming years with the proceeds of such investment."

COMPUGEN LIMITED (NASDAQ: CGEN | Quote | Chart | News | PowerRating) "Up 57.02% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CGEN.php

Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are based on in-silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level. The resulting product candidates are then validated through in vitro and in vivo experimental studies and out-licensed for further development and commercialization under various forms of revenue sharing agreements. Compugen's current collaborations include Biosite, Medarex, Inc., Merck & Co., Inc., Merck Serono, Ortho-Clinical Diagnostics (a Johnson & Johnson company), Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002, Compugen established an affiliate, Evogene Ltd., to utilize certain of the Company's in-silico predictive discovery capabilities in agricultural biotechnology.

CGEN News:

June 23 - Compugen Announces Positive Therapeutic Effects of Novel Peptide in Animal Model of Inflammatory Bowel Disease

Novel Peptide Was Predicted Using Compugen's DAC Blockers Discovery Platform

Compugen Ltd. (Nasdaq: CGEN | Quote | Chart | News | PowerRating) announced today that CGEN-25007, a novel peptide antagonist of gp96 with potent anti-inflammatory activity, has shown positive therapeutic effects in an animal model of inflammatory bowel disease (IBD), a commonly used term covering ulcerative colitis and Crohn's disease.

CGEN-25007 was initially discovered using Compugen's Disease-Associated Conformation (DAC) blockers discovery platform. This platform was designed for the systematic discovery of novel peptides that block proteins of interest from achieving certain disease-associated conformations, a capability that represents immense therapeutic promise in numerous fields. The platform is based on the integration of methods and ideas varying from information theory, through machine learning and statistics, to mathematical analysis for detecting intra-molecular interactions within the protein of interest.

In a recently completed study of TNBS-induced colitis, which is a well accepted animal model of inflammatory bowel disease, administration of CGEN-25007 protected mice from the effects of lethal colitis. Study data showed an increase in survival rate and reversal of weight loss, while mice treated with a negative control showed an irreversible and fatal wasting syndrome. This protective effect of CGEN-25007 was confirmed by improved endoscopic colitis scores, which were similar to those obtained with corticosteroids as a positive control. These results suggest that CGEN-25007 could have a potential therapeutic utility to treat IBD and other autoimmune diseases with a strong inflammatory component, such as rheumatoid arthritis.

Professor Markus F. Neurath, from the University of Erlangen, Germany, who supervised the study and is a recognized world expert in this field, stated, "The results achieved with CGEN- 25007 are very impressive. In the past, we have evaluated numerous molecules in this model but never saw such dramatic effects. If these results continue to be confirmed in further studies, this molecule should represent a very exciting drug candidate for this substantial, and largely unmet medical need." Compugen's discovery of CGEN-25007 through the use of its DAC Blockers Platform was first announced last year following the successful completion of various initial in vitro and in vivo validation studies for acute inflammation. The very high levels of anti-inflammatory activity observed in these earlier acute studies led to the decision by Compugen to also evaluate CGEN-25007 for application in chronic inflammatory conditions.

Dr. Anat Cohen-Dayag, co-CEO at Compugen, said, "We are extremely pleased by the continuing validation of the potent anti-inflammatory activity of CGEN-25007. The excellent results seen in this well accepted disease model for inflammatory bowel disease further support the therapeutic application of this molecule in a number of important medical conditions. Of equal importance is the continuing validation of our unique DAC Blockers Platform."

ABOUT IBD

Inflammatory bowel disease is a chronic, relapsing and remitting inflammatory condition, affecting around two million people in the seven major markets (2007). Due to rising disease rates and evolving diagnostic methods, the market for intestinal anti-inflammatories and IBD drugs is forecasted to continue expanding. The condition is believed to result from the aggregate effect of genetic variations conferring risk of disease and environmental factors affecting the immune system, which combined, lead to an aberrant inflammatory response. In the US, IBD is one of the most prevalent gastrointestinal disease burdens. Currently, this chronic condition is without a medical cure and commonly requires a lifetime of care.

ABOUT GP96

The gp96 protein triggers both the innate and adaptive arms of the immune system and its importance in inflammatory responses has been demonstrated in recent years. gp96 plays an important role in the activation of innate immunity through direct action on various types of immune cells and by promoting the induction of pro-inflammatory cytokines. Moreover, gp96 is essential for Toll-like receptors (TLRs); and, its interaction with ligands of such TLRs amplifies immune responses. Recent findings point to gp96 as a valid target for therapeutic intervention in the treatment of immune-related disorders, such as rheumatoid arthritis and inflammatory bowel disease.

ABOUT THE DAC BLOCKERS DISCOVERY PLATFORM

Compugen's Blockers of Disease-Associated Conformation (DAC Blockers) platform was first disclosed in March 2008, and is one of ten product candidate discovery platforms validated to date by the Company. The DAC Blockers Platform is designed for the prediction and selection of peptides that block proteins from adopting their disease-associated conformations. This is accomplished through the use of a series of proprietary algorithms to identify segments in proteins of interest that, if introduced as synthetic peptides, would prevent the proteins from adopting disease-associated conformations and related activities and thus could have therapeutic benefits. In addition, a key capability of the platform is that the prediction and selection capability enables proteome-wide searches for such peptides in proteins of interest within human, viral and bacterial proteomes. To date, peptide blockers predicted by this platform have been validated experimentally in functional assays for 11 out of 12 protein targets selected for screening. Of these 11 peptides, in addition to CGEN-25007, two others have demonstrated therapeutic potential. Additional peptides targeting other important protein targets are now undergoing experimental validation.

WINNING BRANDS CORPORATION (OTC: WNBD | Quote | Chart | News | PowerRating) "Up 14.29% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/WNBD.php

Winning Brands Corporation manufactures Winning Colours Stain Remover for consumer and commercial use as an eco-responsible alternative to traditional solvents. It is gaining popularity for its remarkable gentleness to skin and delicate surfaces, while still being a powerful and versatile stain remover. Main production takes place at the Grand Rapids, Michigan facility of Surefil LLC. Winning Brands' full product range includes a variety of advanced cleaning solutions, such as its non-toxic SMART Wet Cleaning liquid alternative to Perchloroethylene used in dry cleaning, KIND Laundry Products and CLEAN1 - the first choice in outdoor cleaning. The company's mission is to replace hazardous chemicals in widespread use with safer alternatives. The initial focus is on cleaning products.

WNBD News:

June 22 - Winning Brands Gains Ground in Australia

Winning Colours Stain Remover reaches New South Wales; Moving toward Sydney

Winning Brands Corporation (OTC: WNBD | Quote | Chart | News | PowerRating) (Frankfurt: WMU.F), manufacturer of eco-responsible cleaning solution Winning Colours Stain Remover, added more outlets today amongst Australia's largest franchiser of independent paint specialist retailers, 3D Paint & Colour stores.

For the first time, Winning Colours has moved beyond the State of Queensland into the neighbouring State of New South Wales - home of the country's largest city, Sydney. Just as in the United States, Winning Colours Stain Remover in Australia is creating grass roots support amongst independent retailers first and developing distribution experience in preparation for possible eventual listing in the nation's larger retail chains.

Glen Ford, owner of 3D Inspirations stores in New South Wales has taken delivery of his group's opening inventory in Tweed Heads and Ballina and is keen to see things move forward in that state. "Glen is a very nice man," says Kori Walsh, Winning Colours Brand Ambassador to Australia, "... and he's smart too. Winning Colours Stain Remover has what it takes to become the favourite product in its category here. It's great to work with forward looking business owners who are setting a good pace for Winning Colours in Australia."

Winning Brands CEO Eric Lehner explains why the expansion to the second Australian state is good for the company. "An orderly approach to things is how we like it at Winning Brands - and this is an example. We first put the situation in Queensland into good shape before crossing over into the neighbouring state so that we can advance along the coast toward Sydney, with its population of over 4 million. Like California, Australia has an outdoor lifestyle all year. This lets Winning Colours Stain Remover be applied to a wide range of household uses, continuously, indoors and out. Expansion into the second Australian state is an indicator that the response of the initial Australian consumers to Winning Colours in the State of Queensland is good. This would not have been possible if the word on the street and amongst retailers and their customers about Winning Colours had not been positive. The large chains are aware of us now. They are watching," says Mr. Lehner.

The skin-friendly stain remover and multi-cleaner was developed in Canada but is setting its sights on becoming the world's favourite stain removing product. America now has several thousand independently owned retailers who have gained access to Winning Colours through distributors that have been set up recently. Painters and do-it-yourselfers enjoy the ability of Winning Colours to turn even oil-based messes into a simple clean up with plain water. Winning Brands is training those distributors about Winning Colours Stain Remover to make the most of this expanding store count and convert the retail base to addresses on Winning Brands' store locator service on the company website.

MPHASE TECHNOLOGIES INCORPORATED (OTCBB: XDSL | Quote | Chart | News | PowerRating) "Up 47.76% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/XDSL.php

mPhase Technologies, Inc., through its wholly owned subsidiary AlwaysReady, Inc., is focused on developing and commercializing a new battery technology based on a well-patented phenomenon known as electrowetting, which provides a unique way to store energy and manage power that will revolutionize the battery industry.

XDSL News:

June 23 - mPhase Successfully Manufactures First 6-Inch Silicon-Based Wafer for Smart NanoBattery

mPhase Technologies, Inc. (OTCBB: XDSL | Quote | Chart | News | PowerRating) reported that it has achieved a major milestone in the development of its Smart NanoBattery Technology. mPhase reported that it has successfully manufactured a six-inch silicon-based wafer containing its key membrane (separator) technology. This separator is responsible for keeping the Smart NanoBattery's chemicals separated until activated. The membrane's unique surface and structure allows for control of a liquid on a nanostructured surface.

Each six-inch-diameter silicon wafer contains the separator material for 10 individual Smart NanoBatteries with each battery consisting of 12 "smart cells." Beneath the specialized wafer and contained within each of the smart cells, MEMS processing, microfluidics, and nanotechnology come together to form a unique superhydrophobic honeycomb structure. mPhase has figured out how to use these nano-structured surfaces and technologies to control the battery's liquid electrolytes which mix with the electrodes to create power. In the case of the Smart NanoBattery, the electrolytes can be kept separated from the electrodes until power is needed. Conventional batteries experience power dissipation as soon as the battery is assembled, but mPhase has eliminated this issue by separating the electrolytes from the electrodes. At the precise moment power is needed, the liquid electrolytes are controlled to pass through the porous silicon membrane (separator) where they will then come in contact with the electrodes to provide "Power on Command."

"This fabrication of the silicon membrane is a milestone achievement that represents a key advancement in the STTR development program," said mPhase CEO Ron Durando. "With each step forward, we are making technical advancements that have never been accomplished before. This advancement creates the potential for an unattended device to be powered by a battery with an unsurpassed shelf life that can be electronically controlled."

The Smart NanoBattery is being developed as part of the U.S. Army STTR Program. mPhase was awarded a two year Phase II development contract by the U.S. Army in September 2008 to develop this unique new battery technology for military purposes.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated eight thousand dollars by a third party (Del Mar Corporate Communications) for GSAE advertising and promotional services in May 2009. OTCPicks.com has been compensated five thousand free trading shares from a third party (Onyx Consulting) for this GSAE advertising and promotional program. OTCPicks.com has received twenty million free trading shares from a non-controlling third party for NXHD advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details for CGEN click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index